Trump Accelerates Psychedelic Research

The executive order specifically instructs the FDA to expedite research into substances such as ibogaine and psilocybin, which have gained support among military veteran groups.

During a meeting in the Oval Office, Trump was joined by Joe Rogan and Health Secretary Robert F. Kennedy Jr. to discuss the potential of these treatments.

While advocates hail the decision as a breakthrough for mental health, some medical experts warned of the serious heart risks and safety concerns associated with unregulated psychedelic use.

The administration also announced a $50 million allocation for clinical studies into these drugs.